- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03803163
A Safety, Tolerability and Pharmacokinetics Study of TransCon Treprostinil in Healthy Adult Male Volunteers
January 11, 2019 updated by: Ascendis Pharma A/S
A Phase 1, Open-Label, Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single Doses of TransCon PEG Treprostinil Administered as a Subcutaneous Injection in Healthy Adult Male Volunteers
To determine the maximum tolerated dose (MTD) and assess safety and tolerability of escalating single doses of TransCon PEG treprostinil administered as a subcutaneous injection to healthy male volunteers.
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
20
Phase
- Phase 1
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 50 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- Subject gives voluntary written informed consent to participate in the study.
- Subject is a healthy male between the ages of 18 and 50 years, inclusive, at Screening.
- Subjects must weigh between 60 and 120 kg, inclusive, with a BMI between 19.0-32.0 kg/m2, inclusive at Screening.
- Subject has a medical history, physical examination, vital signs, ECG and clinical laboratory results within normal limits or considered not clinically significant by the Investigator at Screening.
- Subject agrees to abstain from taking any prescription medication for 14 days prior to check-in and to abstain from taking any non-prescription medications (except multivitamins) or herbal supplements for 7 3 days prior to check-in Baseline until discharge from the study (unless prescribed by the Investigator to treat an AE).
- Subject agrees to abstain from consuming alcohol from three days prior to check-in and until discharge from the study.
- Subject agrees to refrain from strenuous exercise from check-in and until discharge from the study.
- Subject is able to communicate effectively with study personnel and be considered reliable, willing and cooperative in terms of compliance with the protocol requirements.
Exclusion Criteria:
- Subject has any clinically relevant abnormality identified during the screening physical examination, 12-lead ECG, or laboratory examinations.
- Subject has a history of anaphylaxis, a previous documented hypersensitivity reaction, or a clinically significant idiosyncratic reaction to any drug.
- Subject has a clinically significant history of neurological, cardiovascular, respiratory, endocrine, hematological, hepatic, renal, gastrointestinal, genitourinary, pulmonary, and/or musculoskeletal disease; glaucoma; a psychiatric disorder, or any other chronic disease, whether controlled by medication or not.
- Subject has a history of postural hypotension, or unexplained syncope.
- Subject has a blood pressure that is less than 90 mmHg systolic or 50 mmHg diastolic at Screening or Baseline.
- Subject has a pulse rate that is greater than 90 bpm after sitting at rest for at least 5 minutes at Screening or Baseline.
- Subject has a history of hypertension.
- Subject has a blood pressure that is greater than 150 mmHg systolic or 90 mmHg diastolic at Screening or Baseline
- Subject has a predisposing condition that could interfere with the absorption, distribution, metabolism, or excretion of drugs.
- Subject has tested positive at the screening visit for HIV infection, HBsAg, or the HCV antibody.
- Subject currently uses tobacco or nicotine products or has a history of tobacco use within six months prior to Baseline.
- Subject has a history of alcohol abuse or a history of or current impairment of organ function reasonably related to alcohol abuse.
- Subject has a history of or current evidence of abuse of licit or illicit drugs, including a positive urine screen for drugs of abuse at Screening or Baseline.
- Subject has a history of abnormal bleeding tendencies.
- Subject has donated blood or plasma or has lost a significant volume of blood (greater than 450 mL) within four weeks prior to Baseline.
- Subject has participated in any investigational drug study within 30 days prior to their initial Screening visit.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: TransCon Treprostinil
|
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
Time Frame: 42 days
|
Safety and tolerability of single doses of TransCon Treprostinil treatment
|
42 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum Plasma Concentration [Cmax] of TransCon Treprostinil
Time Frame: 42 days
|
Pharmacokinetic profile of single doses of TransCon Treprostinil
|
42 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 1, 2015
Primary Completion (Actual)
June 1, 2015
Study Completion (Actual)
June 1, 2015
Study Registration Dates
First Submitted
January 10, 2019
First Submitted That Met QC Criteria
January 11, 2019
First Posted (Actual)
January 14, 2019
Study Record Updates
Last Update Posted (Actual)
January 14, 2019
Last Update Submitted That Met QC Criteria
January 11, 2019
Last Verified
January 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- TCP-PH-101
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy Volunteers
-
AstraZenecaCompletedHealthy Elderly Volunteers | Healthy Young VolunteersUnited States
-
Syndax PharmaceuticalsCompletedHealthy Volunteers | Volunteers | Normal Volunteers | Human VolunteersUnited States
-
Syndax PharmaceuticalsCompletedHealthy Volunteers | Volunteers | Normal Volunteers | Human VolunteersUnited States
-
University Hospital, Clermont-FerrandUnite de Nutrition Humaine UMR 1019- INRAE; Unite MetaGenoPolis INRAE; France...CompletedHealthy Volunteers | Frail VolunteersFrance
-
Newcastle UniversityCompletedGI Glycaemic Index Healthy Volunteers | GL Glycaemic Load Healthy VolunteersUnited Kingdom
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
Galera Therapeutics, Inc.CelerionCompletedHealthy | Healthy VolunteersUnited States
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
PMV Pharmaceuticals, IncRecruitingHealthy VolunteersUnited States
Clinical Trials on TransCon Treprostinil
-
United TherapeuticsWithdrawn
-
Ascendis Pharma A/SActive, not recruiting
-
Ascendis Pharma Growth Disorders A/SActive, not recruitingAchondroplasiaUnited States, Denmark, Ireland, New Zealand, Australia, Canada, Spain
-
Ascendis Pharma A/SActive, not recruitingAchondroplasiaUnited States, Australia, Austria, Denmark, Germany, Ireland, New Zealand, Portugal
-
Ascendis Pharma Growth Disorders A/SEnrolling by invitationAchondroplasiaUnited States, Australia, Denmark, Ireland, Austria, Germany, New Zealand
-
United TherapeuticsTerminatedPulmonary Hypertension Associated With HFpEFUnited States
-
United TherapeuticsCompletedPulmonary Arterial HypertensionUnited States, Canada, India, United Kingdom, Spain, Israel, Australia, Belgium, France, Austria, China, Germany, Ireland, Italy, Mexico, Netherlands, Poland, Portugal, Puerto Rico, Sweden
-
United TherapeuticsTerminatedPulmonary Hypertension | Heart Failure With Preserved Ejection FractionUnited States
-
Ascendis Pharma A/SActive, not recruitingEndocrine System Diseases | Parathyroid Diseases | HypoparathyroidismUnited States, Canada, Denmark, Germany, Italy, Norway
-
United TherapeuticsEnrolling by invitationIdiopathic Pulmonary Fibrosis | Interstitial Lung DiseaseUnited States, Spain, Belgium, Australia, Taiwan, Israel, Korea, Republic of, Italy, France, Argentina, Chile, Denmark, Mexico, Netherlands